Trial Profile
A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms TAHOE
- Sponsors AbbVie; AbbVie Germany
- 22 Jul 2022 This trial has been competed in Romania, according to European Clinical Trials Database record
- 16 Feb 2021 Primary endpoint has not been met. (Overall Survival (OS),as per Results published in the Journal of Thoracic Oncology
- 16 Feb 2021 Results published in the Journal of Thoracic Oncology